{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:00:20Z","timestamp":1789038020883,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41401-025-01703-7","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:34:21Z","timestamp":1767796461000},"page":"888-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sigma-1 receptor positive allosteric modulator promotes neuronal survival and improves cognitive deficits in AD mice via sigma-1 receptor\/ERK pathway"],"prefix":"10.1038","volume":"47","author":[{"given":"Xiao-yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-shu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-chu","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"1703_CR1","unstructured":"Patterson C. World Alzheimer report 2018-The state of the art of dementia research: New frontiers Alzheimer's Disease International, London, 2018. Available from: https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2018\/"},{"key":"1703_CR2","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. 2024;20:3708\u2013821.","DOI":"10.1002\/alz.13809"},{"key":"1703_CR3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"1703_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS. Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer's disease pathogenesis. JAMA Neurol. 2014;71:505\u20138.","journal-title":"JAMA Neurol"},{"key":"1703_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fnagi.2017.00168","volume":"9","author":"M Ayaz","year":"2017","unstructured":"Ayaz M, Sadiq A, Junaid M, Ullah F, Subhan F, Ahmed J. Neuroprotective and anti-aging potentials of essential oils from aromatic and medicinal plants. Front Aging Neurosci. 2017;9:168.","journal-title":"Front Aging Neurosci"},{"key":"1703_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, et al. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2021;7:33.","journal-title":"Nat Rev Dis Primers"},{"key":"1703_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0306-4522(02)00404-9","volume":"115","author":"WH Zheng","year":"2002","unstructured":"Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002;115:201\u201311.","journal-title":"Neuroscience"},{"key":"1703_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.14336\/AD.2019.0813","volume":"11","author":"X Zhao","year":"2020","unstructured":"Zhao X, Li S, Gaur U, Zheng W. Artemisinin improved neuronal functions in Alzheimer\u2019s disease animal model 3xTG mice and neuronal cells via stimulating the ERK\/CREB signaling pathway. Aging Dis. 2020;11:801\u201319.","journal-title":"Aging Dis"},{"key":"1703_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41586-022-04463-0","volume":"603","author":"J Xiong","year":"2022","unstructured":"Xiong J, Kang SS, Wang Z, Liu X, Kuo TC, Korkmaz F, et al. FSH blockade improves cognition in mice with Alzheimer\u2019s disease. Nature. 2022;603:470\u20136.","journal-title":"Nature"},{"key":"1703_CR10","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","volume":"29","author":"WK Self","year":"2023","unstructured":"Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer's disease. Nat Med. 2023;29:2187\u201399.","journal-title":"Nat Med"},{"key":"1703_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nature17391","volume":"532","author":"HR Schmidt","year":"2016","unstructured":"Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human sigma1 receptor. Nature. 2016;532:527\u201330.","journal-title":"Nature"},{"key":"1703_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.tips.2010.08.007","volume":"31","author":"TP Su","year":"2010","unstructured":"Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010;31:557\u201366.","journal-title":"Trends Pharmacol Sci"},{"key":"1703_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28946-w","volume":"13","author":"F Meng","year":"2022","unstructured":"Meng F, Xiao Y, Ji Y, Sun Z, Zhou X. An open-like conformation of the sigma-1 receptor reveals its ligand entry pathway. Nat Commun. 2022;13:1267.","journal-title":"Nat Commun"},{"key":"1703_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.celrep.2018.12.051","volume":"26","author":"E Brailoiu","year":"2019","unstructured":"Brailoiu E, Chakraborty S, Brailoiu GC, Zhao P, Barr JL, Ilies MA, et al. Choline is an intracellular messenger linking extracellular stimuli to IP3-evoked Ca2+ signals through sigma-1 receptors. Cell Rep. 2019;26:330\u20137.e4.","journal-title":"Cell Rep"},{"key":"1703_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.neulet.2012.04.046","volume":"517","author":"A Feher","year":"2012","unstructured":"Feher A, Juhasz A, Laszlo A, Kalman J Jr, Pakaski M, Kalman J, et al. Association between a variant of the sigma-1 receptor gene and Alzheimer\u2019s disease. Neurosci Lett. 2012;517:136\u20139.","journal-title":"Neurosci Lett"},{"key":"1703_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12149-007-0094-z","volume":"22","author":"M Mishina","year":"2008","unstructured":"Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, Oda K, et al. Low density of sigma1 receptors in early Alzheimer\u2019s disease. Ann Nucl Med. 2008;22:151\u20136.","journal-title":"Ann Nucl Med"},{"key":"1703_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2174\/156720511797633232","volume":"8","author":"Y Huang","year":"2011","unstructured":"Huang Y, Zheng L, Halliday G, Dobson-Stone C, Wang Y, Tang HD, et al. Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer\u2019s disease. Curr Alzheimer Res. 2011;8:765\u201370.","journal-title":"Curr Alzheimer Res"},{"key":"1703_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2017.11.010","volume":"339","author":"T Maurice","year":"2018","unstructured":"Maurice T, Strehaiano M, Duhr F, Chevallier N. Amyloid toxicity is enhanced after pharmacological or genetic invalidation of the sigma1 receptor. Behav Brain Res. 2018;339:1\u201310.","journal-title":"Behav Brain Res"},{"key":"1703_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000440864","volume":"16","author":"A Fisher","year":"2016","unstructured":"Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, et al. AF710B, a Novel M1\/sigma1 agonist with therapeutic efficacy in animal models of Alzheimer\u2019s disease. Neurodegener Dis. 2016;16:95\u2013110.","journal-title":"Neurodegener Dis"},{"key":"1703_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bph.12506","volume":"171","author":"L Zvejniece","year":"2014","unstructured":"Zvejniece L, Vavers E, Svalbe B, Vilskersts R, Domracheva I, Vorona M, et al. The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors. Br J Pharmacol. 2014;171:761\u201371.","journal-title":"Br J Pharmacol"},{"key":"1703_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fphar.2019.00223","volume":"10","author":"E Vavers","year":"2019","unstructured":"Vavers E, Zvejniece L, Maurice T, Dambrova M. Allosteric Modulators of sigma-1 receptor: a review. Front Pharmacol. 2019;10:223.","journal-title":"Front Pharmacol"},{"key":"1703_CR22","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1111\/bph.13195","volume":"172","author":"L Guo","year":"2015","unstructured":"Guo L, Chen Y, Zhao R, Wang G, Friedman E, Zhang A, et al. Allosteric modulation of sigma-1 receptors elicits anti-seizure activities. Br J Pharmacol. 2015;172:4052\u201365.","journal-title":"Br J Pharmacol"},{"key":"1703_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/cns.12502","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y, Guo L, Jiang HF, Zheng LT, Zhang A, Zhen XC. Allosteric modulation of sigma-1 receptors elicits rapid antidepressant activity. CNS Neurosci Ther. 2016;22:368\u201377.","journal-title":"CNS Neurosci Ther"},{"key":"1703_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/schbul\/sbab137","volume":"48","author":"J Chen","year":"2022","unstructured":"Chen J, Li G, Qin P, Chen J, Ye N, Waddington JL, et al. Allosteric modulation of the sigma-1 receptor elicits antipsychotic-like effects. Schizophr Bull. 2022;48:474\u201384.","journal-title":"Schizophr Bull"},{"key":"1703_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular abeta and synaptic dysfunction. Neuron. 2003;39:409\u201321.","journal-title":"Neuron"},{"key":"1703_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/JAD-201014","volume":"80","author":"JL Dennison","year":"2021","unstructured":"Dennison JL, Ricciardi NR, Lohse I, Volmar CH, Wahlestedt C. Sexual dimorphism in the 3xTg-AD mouse model and its impact on pre-clinical research. J Alzheimers Dis. 2021;80:41\u201352.","journal-title":"J Alzheimers Dis"},{"key":"1703_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1862437","volume":"2019","author":"S Li","year":"2019","unstructured":"Li S, Zhao X, Lazarovici P, Zheng W. Artemether activation of AMPK\/GSK3beta(ser9)\/Nrf2 signaling confers neuroprotection towards beta-amyloid-induced neurotoxicity in 3xTg Alzheimer\u2019s mouse model. Oxid Med Cell Longev. 2019;2019:1862437.","journal-title":"Oxid Med Cell Longev"},{"key":"1703_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbi.2015.04.014","volume":"49","author":"J Ni","year":"2015","unstructured":"Ni J, Wang X, Chen S, Liu H, Wang Y, Xu X, et al. MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation. Brain Behav Immun. 2015;49:75\u201385.","journal-title":"Brain Behav Immun"},{"key":"1703_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1152\/physrev.00030.2022","volume":"104","author":"M Perluigi","year":"2024","unstructured":"Perluigi M, Di Domenico F, Butterfield DA. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer's disease. Physiol Rev. 2024;104:103\u201397.","journal-title":"Physiol Rev"},{"key":"1703_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102398","volume":"99","author":"N Li","year":"2024","unstructured":"Li N, Liang Y, Zhang L, Xu C, Wang L. Neolignans in magnolia officinalis as natural anti-Alzheimer\u2019s disease agents: a systematic review. Ageing Res Rev. 2024;99:102398.","journal-title":"Ageing Res Rev"},{"key":"1703_CR31","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1093\/brain\/awu107","volume":"137","author":"V Francardo","year":"2014","unstructured":"Francardo V, Bez F, Wieloch T, Nissbrandt H, Ruscher K, Cenci MA. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental Parkinsonism. Brain. 2014;137:1998\u20132014.","journal-title":"Brain"},{"key":"1703_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-022-00998-w","volume":"7","author":"HL Wan","year":"2022","unstructured":"Wan HL, Zhang BG, Chen C, Liu Q, Li T, He Y, et al. Recombinant human erythropoietin ameliorates cognitive dysfunction of APP\/PS1 mice by attenuating neuron apoptosis via HSP90\u03b2. Signal Transduct Target Ther. 2022;7:149.","journal-title":"Signal Transduct Target Ther"},{"key":"1703_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"1703_CR34","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpt.2954","volume":"114","author":"SS Dhruva","year":"2023","unstructured":"Dhruva SS, Kesselheim AS, Woloshin S, Ji RZ, Lu Z, Darrow JJ, et al. Physician perspectives on the Food and Drug Administration\u2019s decision to grant accelerated approval to aducanumab for Alzheimer\u2019s disease. Clin Pharmacol Ther. 2023;114:614\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1703_CR35","doi-asserted-by":"publisher","first-page":"q1327","DOI":"10.1136\/bmj.q1327","volume":"385","author":"O Dyer","year":"2024","unstructured":"Dyer O. Donanemab: FDA experts recommend approval of Alzheimer\u2019s drug. BMJ. 2024;385:q1327.","journal-title":"BMJ"},{"key":"1703_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102012","volume":"90","author":"D Jeremic","year":"2023","unstructured":"Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L. Efficacy and safety of anti-amyloid-beta monoclonal antibodies in current Alzheimer\u2019s disease phase III clinical trials: a systematic review and interactive web app-based meta-analysis. Ageing Res Rev. 2023;90:102012.","journal-title":"Ageing Res Rev"},{"key":"1703_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L Soderberg","year":"2023","unstructured":"Soderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, aducanumab, and gantenerumab\u2014binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics. 2023;20:195\u2013206.","journal-title":"Neurotherapeutics"},{"key":"1703_CR38","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell. 2015;160:1061\u201371.","journal-title":"Cell"},{"key":"1703_CR39","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, et al. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer\u2019s disease: Lauriet. Neurology. 2023;101:e1391\u2013e1401.","journal-title":"Neurology"},{"key":"1703_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13287-022-03231-1","volume":"14","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Shi B, Xu Y, Zhang J, Liu X, Zhou X, et al. Neural stem\/progenitor cell therapy for Alzheimer's disease in preclinical rodent models: a systematic review and meta-analysis. Stem Cell Res Ther. 2023;14:3.","journal-title":"Stem Cell Res Ther"},{"key":"1703_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148368","volume":"912","author":"B Ataei","year":"2024","unstructured":"Ataei B, Hokmabadi M, Asadi S, Asadifard E, Aghaei Zarch SM, Najafi S, et al. A review of the advances, insights, and prospects of gene therapy for Alzheimer\u2019s disease: a novel target for therapeutic medicine. Gene. 2024;912:148368.","journal-title":"Gene"},{"key":"1703_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-3-319-50174-1_10","volume":"964","author":"L Nguyen","year":"2017","unstructured":"Nguyen L, Lucke-Wold BP, Mookerjee S, Kaushal N, Matsumoto RR. Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection. Adv Exp Med Biol. 2017;964:133\u201352.","journal-title":"Adv Exp Med Biol"},{"key":"1703_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","volume":"127","author":"L Nguyen","year":"2015","unstructured":"Nguyen L, Lucke-Wold BP, Mookerjee SA, Cavendish JZ, Robson MJ, Scandinaro AL, et al. Role of sigma-1 receptors in neurodegenerative diseases. J Pharmacol Sci. 2015;127:17\u201329.","journal-title":"J Pharmacol Sci"},{"key":"1703_CR44","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fncel.2018.00314","volume":"12","author":"J Jia","year":"2018","unstructured":"Jia J, Cheng J, Wang C, Zhen X. Sigma-1 receptor-modulated neuroinflammation in neurological diseases. Front Cell Neurosci. 2018;12:314.","journal-title":"Front Cell Neurosci"},{"key":"1703_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-pharmtox-010611-134525","volume":"54","author":"CJ Wenthur","year":"2014","unstructured":"Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol. 2014;54:165\u201384.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1703_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/17460441.2021.1838483","volume":"16","author":"T Maurice","year":"2021","unstructured":"Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021;16:373\u201389.","journal-title":"Expert Opin Drug Discov"},{"key":"1703_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0091-3057(97)00385-7","volume":"59","author":"T Senda","year":"1998","unstructured":"Senda T, Matsuno K, Kobayashi T, Nakazawa M, Nakata K, Mita S. Ameliorative effect of SA4503, a novel cognitive enhancer, on the basal forebrain lesion-induced impairment of the spatial learning performance in rats. Pharmacol Biochem Behav. 1998;59:129\u201334.","journal-title":"Pharmacol Biochem Behav"},{"key":"1703_CR48","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1002\/glia.23850","volume":"68","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ni J, Gao T, Gao C, Guo L, Yin X. Activation of astrocytic sigma-1 receptor exerts antidepressant-like effect via facilitating CD38-driven mitochondria transfer. Glia. 2020;68:2415\u201326.","journal-title":"Glia"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01703-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:02:16Z","timestamp":1774479736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01703-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}